Harvard Health Letter

Ask the doctor: For macular degeneration, which is better, Avastin or Lucentis?

Q. I have wet macular degeneration. I am trying to decide between Avastin and Lucentis. Which drug is better?

A. This is a complicated and very unsettled area. All of the professional organizations for ophthalmologists are struggling with it.

I should also mention right off the bat that I am on Genentech's scientific advisory committee. Genentech developed both Avastin and Lucentis. I am also the chair of the Phase 3 clinical trial of Eylea, another drug for wet macular degeneration, which I expect will be approved by the end of 2011.

To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »